EUROBANK Financial Statements From 2010 to 2026
| 1X8 Stock | EUR 3.94 0.15 3.96% |
Check EUROBANK financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among EUROBANK's main balance sheet or income statement drivers, such as , as well as many indicators such as . EUROBANK financial statements analysis is a perfect complement when working with EUROBANK Valuation or Volatility modules.
EUROBANK |
EUROBANK SA Company Current Valuation Analysis
EUROBANK's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current EUROBANK Current Valuation | 22.88 M |
Most of EUROBANK's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, EUROBANK SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, EUROBANK SA has a Current Valuation of 22.88 M. This is 99.84% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all Germany stocks is 99.86% higher than that of the company.
EUROBANK SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining EUROBANK's current stock value. Our valuation model uses many indicators to compare EUROBANK value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across EUROBANK competition to find correlations between indicators driving EUROBANK's intrinsic value. More Info.EUROBANK SA is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the EUROBANK's earnings, one of the primary drivers of an investment's value.About EUROBANK Financial Statements
EUROBANK stakeholders use historical fundamental indicators, such as EUROBANK's revenue or net income, to determine how well the company is positioned to perform in the future. Although EUROBANK investors may analyze each financial statement separately, they are all interrelated. For example, changes in EUROBANK's assets and liabilities are reflected in the revenues and expenses on EUROBANK's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in EUROBANK SA. Please read more on our technical analysis and fundamental analysis pages.
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia. CRESO PHARMA operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in EUROBANK Stock
EUROBANK financial ratios help investors to determine whether EUROBANK Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EUROBANK with respect to the benefits of owning EUROBANK security.